- Home
- VVPR vs IBO Comparison
VVPR vs IBO Comparison
Compare VVPR & IBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VVPR
- IBO
- Stock Information
- Founded
- VVPR 2014
- IBO 2018
- Country
- VVPR United Kingdom
- IBO United States
- Employees
- VVPR N/A
- IBO N/A
- Industry
- VVPR Power Generation
- IBO
- Sector
- VVPR Utilities
- IBO
- Exchange
- VVPR Nasdaq
- IBO NYSE
- Market Cap
- VVPR 27.0M
- IBO 22.1M
- IPO Year
- VVPR 2016
- IBO 2024
- Fundamental
- Price
- VVPR $2.80
- IBO $0.43
- Analyst Decision
- VVPR
- IBO
- Analyst Count
- VVPR 0
- IBO 0
- Target Price
- VVPR N/A
- IBO N/A
- AVG Volume (30 Days)
- VVPR 10.6M
- IBO 9.7M
- Earning Date
- VVPR 01-01-0001
- IBO 05-23-2025
- Dividend Yield
- VVPR N/A
- IBO N/A
- EPS Growth
- VVPR N/A
- IBO N/A
- EPS
- VVPR N/A
- IBO N/A
- Revenue
- VVPR $79,000.00
- IBO N/A
- Revenue This Year
- VVPR N/A
- IBO N/A
- Revenue Next Year
- VVPR N/A
- IBO N/A
- P/E Ratio
- VVPR N/A
- IBO N/A
- Revenue Growth
- VVPR N/A
- IBO N/A
- 52 Week Low
- VVPR $0.62
- IBO $0.37
- 52 Week High
- VVPR $6.66
- IBO $6.17
- Technical
- Relative Strength Index (RSI)
- VVPR 52.46
- IBO N/A
- Support Level
- VVPR $2.35
- IBO N/A
- Resistance Level
- VVPR $2.90
- IBO N/A
- Average True Range (ATR)
- VVPR 0.49
- IBO 0.00
- MACD
- VVPR -0.18
- IBO 0.00
- Stochastic Oscillator
- VVPR 26.01
- IBO 0.00
About VVPR VivoPower International PLC
Vivopower International PLC is a solar power company. It provides energy infrastructure generation, and distribution solutions and is also engaged in the development, construction, and sale of photovoltaic(PV) solar projects. Its operating segments include Solar Development, Critical Power Services, Sustainable Energy Solutions, Electric Vehicles, and Corporate Office. The majority of the firm's revenue is generated from the Electric Vehicles segment. Geographically its key revenue derives from the Netherlands.
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.